TheraRadar
← Back
Data updated: Mar 29, 2026

DEXCEL

Infectious DiseaseCardiovascularGastroenterology
Specialty

DEXCEL is a specialty pharmaceutical company focused on Infectious Disease, Cardiovascular, Gastroenterology. Key products include HEMADY.

2000
Since
12
Drugs
-
Trials
217
Approved (2yr)

Key Drugs

HEMADY
dexamethasone
Oncology
1 indications · 2019

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

TOFACITINIB CITRATE 2026-02-18
Labeling
TOFACITINIB CITRATE 2026-02-18
Labeling
TOFACITINIB CITRATE 2026-02-18
Labeling
TOFACITINIB CITRATE 2026-02-18
Labeling
TOFACITINIB CITRATE 2026-02-18
Labeling
VENLAFAXINE HYDROCHLORIDE 2026-01-30
Labeling
DICLOFENAC SODIUM 2025-12-31
Labeling
TOFACITINIB CITRATE 2025-11-17
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Infectious Disease 25%
2 drugs
Cardiovascular 25%
2 drugs
Gastroenterology 25%
2 drugs
Oncology 13%
1 drugs
Neurology 13%
1 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Bristol-Myers Squibb big-pharma
Oncology, Gastroenterology, Infectious Disease, Neurology
Pfizer big-pharma
Oncology, Infectious Disease, Gastroenterology
GE HEALTHCARE specialty
Infectious Disease, Neurology, Cardiovascular, Oncology
Merck big-pharma
Oncology, Infectious Disease, Cardiovascular
Novo Nordisk big-pharma
Oncology, Cardiovascular, Infectious Disease, Neurology